80 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
(Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Dr. John Lewicki
Chief Scientific Officer
For biographical information regarding Dr … -Wilson. Ms. Hughes-Wilson has served as our Chief of Patient Access and Commercial Planning, previously titled Head of Patient Access and Commercial
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. Information about … patient access to a medicine. The adaptive pathways concept is an approach to medicines approval that aims to improve patients’ access to medicines
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
; and
WHEREAS, ReproNovo has access to market information, experience in business practices and expert knowledge in relation to the registration … to Control any item of information (including Confidential Information), material or Intellectual Property Right of a Third Party if access by the other Party
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
employees of the Company; (b) all agents and consultants of the Company who have access to or receive material non‑public information about the Company
6-K
EX-3.1
MREO
Mereo Biopharma Group Plc
18 Dec 23
Current report (foreign)
4:10pm
representative) to speak, vote, be represented by a proxy and have access in hard copy or Electronic Form to all Documents which are required … it may be accessed;
(iv)
how to access the Document, information or notice; and
any other information prescribed by the Companies Acts or any other
6-K
EX-99.2
mh5b mvjmhd
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.2
6kfov2fr
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
hwe0q8iqk
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-3.1
8p8m4b7
17 May 22
Current report (foreign)
8:26am
6-K
EX-99.1
grh03 bvm3hv8jdjm9j
14 Mar 22
Current report (foreign)
10:05am
6-K
EX-99.2
b6kq8cfo
2 Nov 21
Current report (foreign)
4:16pm